RU 24969是一种广泛使用的非选择性5-HT1B/1A激动剂,其对5-HT1B受体的Ki值为0.38nM,对5-HT1A受体的Ki值为2.5nM,而对大脑中的其他受体位点亲和力较低。
Cas No.:66611-26-5
Sample solution is provided at 25 µL, 10mM.
RU 24969 is a widely used nonselective 5-HT1B/1A agonist with a Ki value of 0.38nM for the 5-HT1B receptor and 2.5nM for the 5-HT1A receptor, but with lower affinity for other receptor sites in the brain[1]. RU 24969 induces robust hyperlocomotor activity, characterized by increased forward locomotion and a concomitant reduction in fluid consumption[1].
In vitro, 10μM RU-24969 attenuated 21mM K⁺-induced [³H]-5-HT release in cultured rat frontal cortex slices, reducing it by approximately 30%[2].
In vivo, subcutaneous administration of RU 24969 at doses of 0.3, 1, and 3mg/kg produced a dose-dependent reduction in water intake in male SD rats within a 30-45min observation period. In addition, subcutaneous administration of RU 24969 (3mg/kg) significantly increased total forward locomotion within 15-45min after dosing[1]. Administration of RU-24969 at 10mg/kg by intraperitoneal injection decreased extracellular 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA) in rats[2].
References:
[1] Aronsen D, Webster J, Schenk S. RU 24969-produced adipsia and hyperlocomotion: differential role of 5HT 1A and 5HT 1B receptor mechanisms. Pharmacol Biochem Behav. 2014;124:1-4.
[2] Brazell MP, Marsden CA, Nisbet AP, Routledge C. The 5-HT1 receptor agonist RU-24969 decreases 5-hydroxytryptamine (5-HT) release and metabolism in the rat frontal cortex in vitro and in vivo. Br J Pharmacol. 1985;86(1):209-216.
RU 24969是一种广泛使用的非选择性5-HT1B/1A激动剂,其对5-HT1B受体的Ki值为0.38nM,对5-HT1A受体的Ki值为2.5nM,而对大脑中的其他受体位点亲和力较低[1]。RU 24969可显著诱导过度运动,同时表现为向前运动增加及液体摄入减少[1]。
体外实验中,10μM RU-24969可显著抑制21mM K⁺诱导的培养大鼠额叶皮质切片中[³H]-5-HT的释放,抑制幅度约为30%[2]。
体内实验中,皮下注射0.3、1和3mg/kg剂量的RU 24969,在30-45分钟的观察时间内雄性SD大鼠的饮水量呈剂量依赖性降低。皮下注射3mg/kg RU 24969可在15-45分钟内显著提高大鼠总向前运动水平[1]。腹腔注射10mg/kg的RU-24969可显著降低大鼠细胞外5-HT及其代谢产物5-羟基吲哚乙酸(5-HIAA)的水平[2]。
| Animal experiment [1]: | |
Animal models | Male Sprague–Dawley rats |
Preparation Method | Water bottles were removed and 23.75h later, RU 24969 (0-3mg/kg, s.c.) was administered. The water bottles were reintroduced 15min after the RU 24969 injection. Consumption was measured for a 30min period. Fluid consumption was determined by weighing water bottles before and after the test. |
Dosage form | 0.3, 1, 3mg/kg; once; s.c. |
Applications | Administration of 0.3, 1 and 3mg/kg resulted in a dose-dependent reduction in water intake. |
References: | |
| Cas No. | 66611-26-5 | SDF | |
| Canonical SMILES | COC1=CC=C2C(C(C3=CCNCC3)=CN2)=C1 | ||
| 分子式 | C14H16N2O | 分子量 | 228.29 |
| 溶解度 | DMSO: ≥ 30 mg/mL (131.41 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.3804 mL | 21.902 mL | 43.8039 mL |
| 5 mM | 876.1 μL | 4.3804 mL | 8.7608 mL |
| 10 mM | 438 μL | 2.1902 mL | 4.3804 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















